MaxCyte says its clinically validated electroporation technology will help increase efficiency and improve yield of Allogene’s allogeneic CAR-T therapy candidates.
Pfizer-backed biotech Allogene launched in 2018 with a focus on developing allogeneic, or off-the-shelf, chimeric antigen receptor (CAR) T-cell therapies.
To achieve this, the firm has regularly stressed the importance of manufacturing, devoting “considerable time and resources” to the process. Now the firm has inked a deal to use MaxCyte’s ExPERT platform to develop and advance its candidates through to commercialization.
“MaxCyte’s ExPERT Platform is an electroporation technology capable of high-performance delivery into multiple cell types including primary cells, stem cells, and cell lines with minimal disturbance resulting in efficiencies routinely at greater than 90%,” a spokesperson from MaxCyte told this publication.
The electroporation is based on the reversible permeability of membranes in the presence of an electrical field, creating a universal transfection technology the firm says is capable of high-performance delivery of virtually any molecule, including DNA, RNA, proteins and cell lysates with minimal cell disturbance.
Click here to read more via BioProcess International